RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $148 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $148.
November 21, 2023 | 5:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst reaffirms Outperform rating on Sarepta Therapeutics and maintains a $148 price target.
The reiteration of an Outperform rating by a major analyst like RBC Capital, along with the maintenance of a high price target, is a positive signal to investors and could lead to increased investor confidence and a potential short-term rise in SRPT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100